Jakafi is a registered trademark of Incyte Corporation.
© 2016, Incyte Corporation. All rights reserved. RUX-2053 10/16
Important Safety Information
Jakafi can cause serious side effects, including:
Low blood counts: Jakafi® (ruxolitinib) may cause
your platelet, red blood cell, or white blood cell counts
to be lowered. If you develop bleeding, stop taking
Jakafi and call your healthcare provider. Your healthcare
provider will perform blood tests to check your blood
counts before you start Jakafi and regularly during your
treatment. Your healthcare provider may change your
dose of Jakafi or stop your treatment based on the
results of your blood tests. Tell your healthcare provider
right away if you develop or have worsening symptoms
such as unusual bleeding, bruising, tiredness, shortness
of breath, or a fever.
Infection: You may be at risk for developing a serious
infection during treatment with Jakafi. Tell your
healthcare provider if you develop any of the following
symptoms of infection: chills, nausea, vomiting, aches,
weakness, fever, painful skin rash or blisters.
Skin cancers: Some people who take Jakafi have
developed certain types of non-melanoma skin cancers.
Tell your healthcare provider if you develop any new or
changing skin lesions.
Increases in cholesterol: You may have changes in
your blood cholesterol levels. Your healthcare provider
will do blood tests to check your cholesterol levels
during your treatment with Jakafi.
The most common side effects of Jakafi include:
low platelet count, low red blood cell counts, bruising,
These are not all the possible side effects of Jakafi.
Ask your pharmacist or healthcare provider for more
information. Tell your healthcare provider about any
side effect that bothers you or that does not go away.
Before taking Jakafi, tell your healthcare provider
about: all the medications, vitamins, and herbal
supplements you are taking and all your medical
conditions, including if you have an infection, have or
had tuberculosis ( TB) or have been in close contact
with someone who has TB, have or had hepatitis B,
have or had liver or kidney problems, are on dialysis,
had skin cancer, or have any other medical condition.
Take Jakafi exactly as your healthcare provider tells you.
Do not change your dose or stop taking Jakafi without
first talking to your healthcare provider. Do not drink
grapefruit juice while on Jakafi.
Women should not take Jakafi while pregnant or
planning to become pregnant, or if breast-feeding.
Please see the summary of important information
on the next page, which includes a more complete
discussion of the risks associated with Jakafi.
You are encouraged to report negative side
effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch, or call 1-800-FDA-1088.
When you’re living with a rare disease like PV, and HU
didn’t work for you, the path you take to move your
treatment journey forward depends on your individual
condition, as well as the decisions you make with your
Discover what’s possible with Jakafi®— the first
and only prescription medicine approved by the FDA
for people with PV who have already taken a medicine
called hydroxyurea (HU) and it did not work well enough
or they could not tolerate it.
A key clinical trial showed that Jakafi helped
• Maintain their hematocrit (red blood cell volume)
level without the need for phlebotomy
• Reduce spleen size
How your PV progresses and how you may respond
to Jakafi depends on your specific circumstances.
Your individual results may vary. Only your Healthcare
Professional can determine if Jakafi is right for you.
Discover what’s possible for you. Talk with your
Healthcare Professional about Jakafi today.
Move your journey in the direction
that’s right for you.
Get more information about Jakafi.
Explore the possibilities at